Table 1

Disruption of AKA95-RII Anchoring or cAMP/PKA Inhibition Does Not Inhibit Mitotic Chromosome Condensation

InhibitorMitotic index
(Percent)
None (∼25 pl FITC-dextran)88 ± 8
α-AKAP95 (polyclonal; ∼2 pg)17 ± 7
α-AKAP95 (∼2 pg) + GST-AKAP95Δ1-386 (250 pg)80 ± 6
Ht31 (50 nM)79 ± 8
Ht31-P (50 nM)82 ± 6
PKI (10 nM)85 ± 5
Rp-8-Br-cAMPS (10 μM)90 ± 4
  • Nuclei of HeLa cells synchronized in interphase were injected with either 2–5 pg affinity-purified polyclonal anti–AKAP95 antibodies, 2–5 pg anti–AKAP95 antibodies with 250 pg GST-AKAP95Δ1-386 peptide, 50 nM RII-anchoring inhibitor peptide Ht31, 50 nM control Ht31-P peptide, 10 nM PKI, or 10 μM cAMP antagonist Rp-8-Br-cAMPS. Injection volumes were 25–50 pl. Control nuclei were injected with 25–50 pl FITC-dextran only. Cells were released from the thymidine block and synchronized with 1 μM nocodazole to induce M phase arrest. After 17 h in nocodazole, mitotic indexes were determined. Data from 30–50 injected cells per treatment are reported. (Similar results were obtained regardless of the site of injection within the cells; data not shown).